TMEM182

Across TCGA pan-cancer cohorts, TMEM182 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM182 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher TMEM182 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM182 expression acts as an unfavorable survival marker.

BRCA and SCLC are the cancer types where TMEM182 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.104	0.579	<.001	30	view →
SCLC	DFS	Median	All	0.205	0.631	.010	15	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TMEM182–BRCA (OS)

Open the BRCA breakdown →